ActivistsInvestorsTrumpPoliticiansSerenityCitriniSemianalysisTradeArbitrageSearch

Andrew Law / Caxton

directional-only · 31-DEC-2025 → 31-MAR-2026

AUM $4,024,354 · 7 positions · top-10 100.0% · SEC filing history →

13FScore 67/100 — cloning their disclosed top holdings over ~4.7y returned +12%/yr vs S&P +10%/yr (alpha +2%/yr), ahead of the market in 53% of quarters. Cloneable 13F equity book only — excludes hedges/shorts/non-US.

New positions

Issuer% bookValueSince entryConvictionBusinessTags
$ALXO · ALX ONCOLOGY HLDGS INC1.0%$41,996+5%MedNASDAQ

Added to (≥+25% shares)

Issuer% bookΔ sharesSince addConvictionBusinessTags
none

Top holdings now

Issuer% bookSince entryBusinessTags
$GQ9 · SPDR GOLD TR81.5%An exchange-traded fund in the State Street SPDR family (GLD) that holds physical gold bullion in trust to track the price of gold.
$BRK.B · BERKSHIRE HATHAWAY INC DEL8.7%+40% Q4 '23Berkshire Hathaway is a diversified holding company led by Warren Buffett, owning insurance, railroad, energy, and manufacturing businesses alongside a large portfolio of public equities.S&PBitget →
$KYTX · KYVERNA THERAPEUTICS INC4.0%-70% Q1 '24Cell therapy biotech for autoimmune diseasesNASDAQ
$LXEO · LEXEO THERAPEUTICS INC2.0%-65% Q4 '23Gene therapy biotech (cardiac, CNS diseases)NASDAQ
$XFOR · X4 PHARMACEUTICALS INC1.6%-5% Q4 '25Biotech for rare immune diseasesNASDAQ
$IKT · INHIBIKASE THERAPEUTICS INC1.2%-35% Q4 '24Neurodegenerative disease therapeutics biotechNASDAQ
$ALXO · ALX ONCOLOGY HLDGS INC1.0%+5% Q1 '26NASDAQ

Since entry / add = price change to the latest close (31-MAR-2026 book marked to market). Top holdings measure from the quarter-end when the name first entered the filer's disclosed top holdings (tagged e.g. Q1 '26); new & added positions measure from this quarter's quarter-end. Based on disclosed 13F snapshots — an approximation of entry, not the manager's actual cost basis. Generated 2026-07-20 · Alpha-Investor tracker